Overview
Xarelto bleeding lawsuits — MDL 2592, In re Xarelto Products Liability Litigation, E.D. La., Judge Eldon E. Fallon (per JPML). Plaintiffs alleged Xarelto (rivaroxaban, Bristol-Myers Squibb and Janssen) led to serious bleeding, including fatal intracranial hemorrhage, and that its warnings were inadequate (per complaints). The FDA issued a safety communication on serious bleeding in 2013 (per FDA). Bristol-Myers Squibb and Janssen reached a $775 million settlement of the consolidated litigation in 2020 (per public reports); $93 million in common benefit fees was approved on March 23, 2020 (per court orders and reports). The JPML closed MDL 2592 on February 11, 2026 (per the JPML MDL statistics report). No further payout amount is available or can be promised.
Status of the science / claims: Xarelto (rivaroxaban) is an oral anticoagulant. Plaintiffs alleged it led to serious bleeding, including fatal intracranial hemorrhage, and that warnings were inadequate (per complaints). The FDA issued a safety communication on serious bleeding in 2013 (per FDA). The parties resolved the consolidated litigation through a 2020 settlement (per public reports).
Companies involved
Settlement amounts
Global MDL settlement: $775 million (per public reports, 2020). Common benefit fees of $93 million approved on March 23, 2020 (per court orders and reports). MDL 2592 formally closed Feb 11, 2026 (per JPML statistics report). Individual claim amounts varied under the settlement program; no amount can be promised.
Case count
| Month | Filed cases | Δ |
|---|---|---|
| Jan 1, 2020 | 0 | -4000 |
| Jan 1, 2018 | 4,000 | +2800 |
| Jan 1, 2016 | 1,200 | +1000 |
| Jan 1, 2014 | 200 | — |
Key dates
- February 11, 2026MDL 2592 formally closed (per JPML MDL statistics report)
- March 23, 2020$93 million common benefit fees approved (per court orders and reports)
- January 1, 2020BMS and Janssen agree to a $775 million settlement (per public reports)
- October 1, 2014MDL 2592 established in E.D. La., Judge Fallon (per JPML)
- May 10, 2013FDA safety communication: serious bleeding risks with Xarelto (per FDA)
Updates
- Updated Sep 1, 2026JPML closed MDL 2592 on Feb 11, 2026 (per JPML MDL statistics report) — consolidated proceeding formally ended after the 2020 settlement.
- Updated Aug 1, 2026Seeded from research (Aug 31, 2026): MDL 2592 (E.D. La., Judge Fallon); $775 million settlement in 2020 (per public reports).
Notable filings
- — Common benefit fee order — $93M (MDL 2592, E.D. La.) [source] — $93 million in common benefit fees approved (per court orders and reports, March 23, 2020).
FAQ
What is the Xarelto bleeding lawsuit about?
Plaintiffs alleged Xarelto (rivaroxaban) led to serious bleeding, including fatal intracranial hemorrhage, and that the drug’s warnings were inadequate (per complaints). The MDL was In re Xarelto Products Liability Litigation, MDL 2592, E.D. La., Judge Eldon E. Fallon (per JPML).
How much did the settlement pay?
Bristol-Myers Squibb and Janssen reached a $775 million settlement of the consolidated litigation in 2020 (per public reports). Common benefit fees of $93 million were approved on March 23, 2020 (per court orders and reports).
Is the Xarelto MDL still open?
No. The JPML closed MDL 2592 on February 11, 2026 (per the JPML MDL statistics report), marking the formal end of the consolidated proceeding after the 2020 settlement.
How much did individual claims pay?
Individual claim amounts varied under the settlement program depending on the injury and documentation; no outcome or amount can be promised. Per-claim figures were not published centrally (per the settlement program).
Who were the defendants?
Bristol-Myers Squibb and Janssen Pharmaceuticals (makers of Xarelto/rivaroxaban) (per complaints and public reports).
What did the FDA say?
The FDA issued a safety communication on serious bleeding in 2013 (per FDA).
Can I still file a Xarelto claim?
The consolidated MDL settlement resolved the consolidated claims (per the settlement program, 2020). For potential separate claims, consult a licensed attorney — this page is reference only.
Think this matters to you?
This page is neutral reference material — not legal advice. If you were affected, the next step is a free case review with a licensed attorney working this matter.
Start free case review →